Journal
CANCER IMMUNOLOGY RESEARCH
Volume 5, Issue 7, Pages 571-581Publisher
AMER ASSOC CANCER RESEARCH
DOI: 10.1158/2326-6066.CIR-16-0376
Keywords
-
Categories
Funding
- NIH [1R01CA173750-01, 1R21NS089802-01]
- NCI Cancer Center Support grant [P30CA125123]
- American Brain Tumor Association Basic Research Fellowship [BRF160004]
- Alex Lemonade Stand Foundation
- Curing Kids Cancer
- Cookies for Kids Cancer
- James S. McDonnell Foundation
Ask authors/readers for more resources
Glioblastoma (GBM) is the most aggressive primary brain tumor in adults and is virtually incurable with conventional therapies. Immunotherapy with T cells expressing GBM-specific chimeric antigen receptors (CAR) is an attractive approach to improve outcomes. Although CAR T cells targeting GBM antigens, such as IL13 receptor subunit alpha 2 (IL13R alpha 2), HER2, and EGFR variant III (EGFRvIII), have had antitumor activity in preclinical models, early-phase clinical testing has demonstrated limited antiglioma activity. Transgenic expression of IL15 is an appealing strategy to enhance CAR T-cell effector function. We tested this approach in our IL13R alpha 2-positive glioma model in which limited IL13R alpha 2-CAR T-cell persistence results in recurrence of antigen-positive gliomas. T cells were genetically modified with retroviral vectors encoding IL13R alpha 2-CARs or IL15 (IL13R alpha 2-CAR. IL15 T cells). IL13R alpha 2-CAR. IL15 T cells recognized glioma cells in an antigen-dependent fashion, had greater proliferative capacity, and produced more cytokines after repeated stimulations in compar-ison with IL13R alpha 2-CAR T cells. No autonomous IL13R alpha 2-CAR. IL15 T-cell proliferation was observed; however, IL15 expression increased IL13R alpha 2- CAR T-cell viability in the absence of exogenous cytokines or antigen. In vivo, IL13R alpha 2-CAR. IL15 T cells persisted longer and had greater antiglioma activity than IL13R alpha 2-CAR T cells, resulting in a survival advantage. Gliomas recurring after 40 days after T-cell injection had downregulated IL13R alpha 2 expression, indicating that antigen loss variants occur in the setting of improved T-cell persistence. Thus, CAR T cells for GBM should not only be genetically modified to improve their proliferation and persistence, but also to target multiple antigens. Summary: Glioblastoma responds imperfectly to immunotherapy. Transgenic expression of IL15 in T cells expressing CARs improved their proliferative capacity, persistence, and cytokine production. The emergence of antigen loss variants highlights the need to target multiple tumor antigens. (C)2017 AACR.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available